There are signs that investors are rotating capital away from tech stocks. Which means it could be time to consider dividend stocks. Interest rates are expected to move lower or at least stabilize in 2026. This encourages investors to move from high-multiple growth stocks to long-duration dividend stocks.
But what should you look for? Let's take as a given that investors should look for stocks with a dividend yield of around 3%. The most recent, if not necessarily reliable, inflation data we have puts inflation around 2.7%. It's too early to tell if inflation will increase as monetary power loosens and stimulus is added to the economy. Nevertheless, a dividend of at least 3% will be needed to keep your investments ahead of inflation.
These stocks provide investors with the benefit of reliable quarterly distributions that you can accept as cash in your bank account or that you can reinvest to increase your position in the stock.
However, you should expect more from dividend stocks than reliable income. The stocks on this list also have a history of delivering a solid total return, which includes stock price appreciation to go along with a growing dividend. That's how you maximize the benefits of compounding.
Dividend Stocks to Buy: AbbVie
AbbVie Inc. (NYSE: ABBV) is hardly considered a comeback story. ABBV stock is up nearly 30% in 2025, and analysts are raising their price targets for the next 12 months. Outside of a company like Eli Lilly & Co. (NYSE: LLY), which is in a dominant position in the GLP-1 market, it's been a rough year for pharmaceutical stocks.
The key for AbbVie is that the company has successfully replaced the revenue it's losing as its blockbuster Humira drug reached the patent cliff. But AbbVie's patent-protected Skyrizi and Rinvoq are picking up the slack, and the company has a deep pipeline and a robust balance sheet that gives the company the firepower to get them across the finish line.
AbbVie is also a dividend king, meaning it's increased its dividend for at least 50 consecutive years. The yield as of this writing is 2.84% and is well covered by the company's cash flow.
Dividend Stocks to Buy: Bristol-Myers Squibb
Bristol-Myers Squibb Co. (NYSE: BMY) has had a challenging few years as investors have cooled on large pharmaceutical names facing patent expirations. But value-minded dividend investors may find an opportunity as the stock appears deeply discounted relative to its historical valuation. The company trades at a forward P/E under 10 and offers a dividend yield in the 4.9% range—well above the market average.
The fundamentals remain solid. Bristol-Myers is focusing on expanding newer drugs like Eliquis, Opdivo, and Reblozyl while investing in its pipeline of oncology and immunology therapies. Near-term results may stay lumpy, but with a steady cash flow profile and consistent earnings support, the dividend looks safe.
For contrarian investors, BMY provides a classic example of a high-yield stock with stabilization and upside potential if sentiment improves in 2026.
Dividend Stocks to Buy: Pepsi
PepsiCo Inc. (NASDAQ: PEP) offers a blend of income reliability and defensive growth that fits well in a 2026 portfolio rotation. While consumer staples stocks have lagged during the speculative surge into AI and tech, that underperformance has set the stage for better entry points. PepsiCo's diversified product portfolio, from beverages to snacks, gives it pricing power and resilience even in a slower economy.
The company has increased its dividend for more than 50 years, placing it among the Dividend Kings. Its yield of roughly 3% is comfortably above inflation, and its payout ratio of around 70% indicates room for further growth. As input cost pressures ease and global demand normalizes, PepsiCo looks positioned for mid-single-digit earnings growth alongside continued capital returns.
Dividend Stocks to Buy: Enbridge
Next on my list is Enbridge Inc. (NYSE: ENB), which is an energy infrastructure company. For starters, Enbridge has a high-yield dividend of 5.66% as of December 26. An above average yield can be a value trap, but that doesn't appear to be the case with Enbridge.
The catalyst is likely to be the company's positioning with heavy crude oil. This is the type of crude oil needed for applications like diesel fuel. Unlike light crude oil, heavy crude inventories are low. That means countries with heavy oil resources, such as Canada, will benefit.
Enbridge is the largest transporter of Western Canadian select. And the company has long-term contracts, a stable tolling model, and expansion opportunities that give investors exposure without the upstream risk.
Dividend Stocks to Buy: Texas Instruments
Texas Instruments Inc. (NASDAQ: TXN) stands out in the semiconductor space as one of the most dependable dividend payers. While many chipmakers lean heavily on cyclical end markets, TI's strategy focuses on analog and embedded chips used in long-duration industrial and automotive applications—segments that provide stable, recurring demand.
The company has raised its dividend for 20 consecutive years, and at a current yield near 3.3%, TXN offers an appealing blend of income and long-term growth. With its disciplined capital allocation, massive free cash flow generation, and conservative balance sheet, Texas Instruments embodies the kind of steady compounder that dividend investors can hold through multiple market cycles.
The Bottom Line on High-Powered Dividend Stocks for 2026
As the market transitions from speculative tech toward more income-focused investing, dividend stocks are regaining their appeal. The five companies highlighted here: AbbVie, Bristol-Myers Squibb, PepsiCo, Enbridge, and Texas Instruments, combine reliable dividend growth with the potential for solid total returns.
They operate in diverse sectors, ranging from healthcare and consumer staples to energy and semiconductors, providing investors with balance and resilience across different market conditions. In 2026, when interest rates may finally stabilize and inflation holds near current levels, long-term dividend payers like these could quietly outperform, rewarding patient investors with steady income and compounding gains over time.
No comments:
Post a Comment